An anti-CD3/anti–CLL-1 bispecific antibody for the treatment of acute myeloid leukemia

Acute myeloid leukemia (AML) is a major unmet medical need. Most patients have poor long-term survival, and treatment has not significantly changed in 40 years. Recently, bispecific antibodies that redirect the cytotoxic activity of effector T cells by binding to CD3, the signaling component of the...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood
Päätekijät: Leong, Steven R., Sukumaran, Siddharth, Hristopoulos, Maria, Totpal, Klara, Stainton, Shannon, Lu, Elizabeth, Wong, Alfred, Tam, Lucinda, Newman, Robert, Vuillemenot, Brian R., Ellerman, Diego, Gu, Chen, Mathieu, Mary, Dennis, Mark S., Nguyen, Allen, Zheng, Bing, Zhang, Crystal, Lee, Genee, Chu, Yu-Waye, Prell, Rodney A., Lin, Kedan, Laing, Steven T., Polson, Andrew G.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2017
Aiheet:
Myeloid Neoplasia
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5290988/
https://ncbi.nlm.nih.gov/pubmed/27908880
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-08-735365
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia